Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) will release its third-quarter 2025 financial results after market close on Wednesday, October 22, 2025. The company will host a conference call to discuss results and corporate updates beginning at 4:30 p.m. Eastern Time the same day.
Investors may join by phone (U.S. dial-in 844-850-0543; outside U.S. 412-317-5199) or listen live via the company webcast on the Viking IR Webcasts page. A telephone replay will be available through October 29, 2025 with replay access code 8625334, and a webcast archive will be posted on the Webcasts page for 30 days.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, has announced its participation in four upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (Sept 3-5), Morgan Stanley Global Healthcare Conference (Sept 8-10), Bernstein Healthcare Forum (Sept 23-25), and Stifel Virtual Cardiometabolic Forum (Sept 30). Management will engage in fireside chats, presentations, and investor meetings.
Live webcasts will be available for the Morgan Stanley and Bernstein events through Viking's website, with replays accessible afterward in the Investors & Media section.
Viking Therapeutics (NASDAQ: VKTX) announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an oral tablet formulation targeting obesity treatment. The study achieved both primary and secondary endpoints, demonstrating significant weight loss benefits.
Key highlights include: Up to 12.2% (26.6 lbs) mean weight loss in treated patients compared to 1.3% (2.9 lbs) for placebo after 13 weeks. The trial showed impressive efficacy with up to 97% of subjects achieving ≥5% weight loss and up to 80% achieving ≥10% weight loss. The drug demonstrated a favorable safety profile with 99% of GI-related adverse events being mild or moderate.
An exploratory maintenance dosing cohort showed promising results, suggesting effective weight maintenance may be achieved at lower doses (30mg) after initial treatment with higher doses.
Viking Therapeutics (NASDAQ:VKTX) reported Q2 2025 financial results and pipeline updates. The company has initiated the Phase 3 VANQUISH registration trials for VK2735 in obesity, following successful Phase 2 results showing up to 14.7% weight reduction. The VANQUISH program includes two studies targeting approximately 5,600 patients total.
Viking completed enrollment in the Phase 2 VENTURE-Oral dosing trial for their oral obesity treatment, with results expected in 2H25. The company is also advancing its amylin agonist program with an IND planned for Q4 2025. Financial results showed a net loss of $65.6 million for Q2, with a strong cash position of $808 million as of June 30, 2025.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, will release its Q2 2025 financial results on Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide corporate updates. Investors can join via phone or watch the webcast through Viking's website. A replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days.
Viking Therapeutics (NASDAQ: VKTX) has launched its Phase 3 VANQUISH clinical program for VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The program consists of two major studies: VANQUISH-1, targeting 4,500 obese adults, and VANQUISH-2, targeting 1,100 obese/overweight adults with type 2 diabetes.
The 78-week trials will evaluate three dosing arms (7.5mg, 12.5mg, 17.5mg) against placebo, with the primary endpoint measuring body weight change. The announcement follows successful Phase 2 VENTURE study results, where VK2735 achieved up to 14.7% body weight reduction and demonstrated favorable safety profiles with mostly mild to moderate adverse events.
Viking also plans to initiate a study for monthly maintenance dosing and expects to report Phase 2 results for the oral formulation in late 2025.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has announced its participation in four major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference (June 3-5) in Chicago - Including corporate presentation and fireside chat
- Jefferies Global Healthcare Conference (June 3-5) in New York - Featuring corporate presentation with webcast availability
- Goldman Sachs Global Healthcare Conference (June 9-11) in Miami
- Scotiabank Healthcare Canadian Investor Day (June 17) in Toronto
The company will conduct one-on-one meetings at all events, with a live webcast available for the Jefferies presentation through Viking's website.
Viking Therapeutics (VKTX) has reported its Q1 2025 financial results and provided key updates on its clinical pipeline. The company ended the quarter with a strong cash position of $852 million, down from $903 million in December 2024. The quarter saw a net loss of $45.6 million ($0.41 per share), compared to $27.4 million ($0.26 per share) in Q1 2024.
Key developments include:
- Phase 3 trials for subcutaneous VK2735 obesity treatment expected to begin in Q2 2025
- Completion of enrollment in Phase 2 VENTURE-Oral Dosing trial, with data expected in 2H 2025
- New manufacturing agreement with CordenPharma for VK2735 commercialization
- Advancement of novel amylin agonist program with IND filing planned for 2H 2025
R&D expenses increased to $41.4 million from $24.1 million year-over-year, while G&A expenses rose to $14.1 million from $10.0 million.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has scheduled its first quarter 2025 financial results release for April 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss financial results and corporate updates. Participants can join via phone (U.S.: 844-850-0543; International: 412-317-5199) or through the company's website. A replay will be available until April 30, 2025, using access code #8779272.
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint focuses on body weight change after 13 weeks, with results expected in 2H25. Previous Phase 1 results showed promising outcomes, with weight reductions up to 8.2% after 28 days and up to 8.3% at follow-up. The drug demonstrated favorable safety profile with 99% of adverse events being mild or moderate.
Notably, Viking is also developing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in 1H25.